Al Altomari, Chairman and CEO
Agile Therapeutics
Charlene Banard, Global Head of Technical Operations Cell & Gene Therapy Strategy, Innovation Pipeline and PMO
Novartis
Jeffrey Berkowitz, Board Member
H. Lundbeck A/S
Liz Bywater, Ph.D., President
Bywater Consulting Group
Ron Cohen, M.D., President & CEO
Acorda Therapeutics
Laurie Cooke, CEO
Healthcare Businesswomen's Association (HBA)
John Crowley, Chairman and CEO
Amicus Therapeutics
Rich Daly, Chief Operating Officer
Beyond Spring
Raúl Díaz, Animal Health Large Molecules Biopharm. Operations
MSD, Montes Claros, MG, Brazil
Tom Dilenge, President, Advocacy, Law & Public Policy Division
Biotechnology Innovation Organization
Joseph Ferra, CFO
Syros Pharmaceuticals
Anu Hans, VP, Strategic Initiatives
Janssen Supply Chain
Fred Hassan, Managing Director
Warburg Pincus
Paul Hastings, President and CEO
Nkarta Therapeutics
Axel Hoos, M.D., Ph.D., SVP Oncology R&D
GSK
John Hubbard, Ph.D., Emeritus Editorial Advisory Board Member
Life Science Leader
Mitchell Katz, Ph.D., Vice President, Development Operations
Ferring Pharmaceutical, Inc.
Mary Rose Keller, VP, Head Of Clinical Operations
Acrivon Therapeutics
Rachel King, CEO
GlycoMimetics
Suresh Kumar, Former EVP External Affairs
Sanofi
John LaMattina, Ph.D., Sr. Partner
PureTech Health
Jacks Lee, SVP Global Manufacturing and Supply
Merck
Martin Lehr, CEO
Context Therapeutics
Sandy Macrae, Ph.D., President & CEO
Sangamo Therapeutics
Ken Moch, Former President & CEO
Cognition Therapeutics
Carol Nacy, Ph.D., CEO
Sequella
Francois Nader, M.D., Chairman of the Board
Acceleron Pharma
Sandra E. Poole, Chief Operating Officer
Mythic Therapeutics
Dennis Purcell, Founder & Sr. Advisor
Aisling Capital
David Pyott, Chairman of the Board
Bioniz Therapeutics
Chandra Ramanathan, Ph.D., MBA, VP & Head, East Coast Innovation Center
Bayer
Stephen Rapundalo, Ph.D., President & CEO
MichBio
Pamela Reilly Contag, Ph.D., Cofounder and CEO
BioEclipse Therapeutics
John Reynders, Ph.D., VP, R&D Strategy, Program Management, and Data Sciences
Alexion
James Robinson, Emeritus Editorial Advisory Board Member
Life Science Leader
Tomasz Sablinski, M.D., Ph.D., Managing Director, Head of Clinical Development
Auven Therapeutics
Jim Scibetta, CEO
Maverick Therapeutics
Chhaya Shah, SVP Technical Operations
Radius Health
Allan Shaw, Independent Consultant
Brandi Simpson, VP Business and Corporate Development
Voyager Therapeutics
Andrew Skibo, Emeritus Editorial Advisory Board Member, Life Science Leader
MedImmune / AstraZeneca
Jason Urban, Ph.D., Sr. Dir. Quality Risk Management
Alexion
Thomas Wiggans, Founder, CEO, Chairman
Dermira
Leslie Williams, Entrepreneur, Executive, Board Member, Mentor
Tim Wright, CEO
MiMedx

IN THIS MONTH'S ISSUE

  • Bloated COVID Relief Package Misses Mark
    3/8/2021

    In his final column, John McManus discusses the difficult position pharma companies are in now from a political standpoint and the COVID relief bills.

  • What I Learned As A Teacher That Made Me A Better Leader
    4/1/2021

    Before I started my career in the pharmaceutical industry, I was a chemistry and biology teacher. While my days in the classroom now feel like a lifetime ago, a day rarely passes that I don't draw upon the range of skills I honed back then.

  • Turn COVID-19 Supply Chain/Manufacturing Challenges Into Opportunities
    4/1/2021

    While there are no quick and easy fixes to overcoming COVID-related supply chain and manufacturing challenges, they do present opportunities for modernizing supply chains and manufacturing capabilities.

  • A Q&A With Bernie Zeiher Of Astellas
    4/1/2021

    Bernie Zeiher Of Astellas took on the dual role of CMO & President of Development in April 2018. Here he discusses how he adjusted to that job and some of the best practices he’s learned along the way.

  • Insights On How Outsourcing Decisions Are Made
    4/1/2021

    How does your company’s approach to making outsourcing decisions compare with others in the industry? Data from ISR’s CDMO outsourcing models report highlights common practices that, when adopted, may improve outsourcing outcomes from drug innovators’ perspectives.

@LIFESCILEADER1